Full Coverage
New Alzheimer's drug aducanumab: cost, side effects, timeline and other questions answered
By Jacqueline Howard
FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries
By Tricia Neuman & Juliette Cubanski
The FDA's Approval Of Aduhelm: Potential Implications Across A Wide Range Of Health Policy Issues And Stakeholders
By Rachel E Sachs
U.S. FDA faces mounting criticism over Alzheimer's drug approval
By Julie Steenhuysen & Deena Beasley
Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug
By Berkeley Lovelace & Berkeley Lovelace Jr.
Three F.D.A. Advisers Resign Over Agency's Approval of Alzheimer's Drug (Published 2021)
By Pam Belluck & Rebecca Robbins
Third member of U.S. FDA advisory panel resigns over Alzheimer's drug approval
By Julie Steenhuysen & Carl O'Donnell